Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

BACKGROUND: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. METHODS: A total of 184...

Descripción completa

Detalles Bibliográficos
Autores principales: Marmorino, Federica, Salvatore, Lisa, Barbara, Cecilia, Allegrini, Giacomo, Antonuzzo, Lorenzo, Masi, Gianluca, Loupakis, Fotios, Borelli, Beatrice, Chiara, Silvana, Banzi, Maria Chiara, Miraglio, Emanuela, Amoroso, Domenico, Dargenio, Francesco, Bonetti, Andrea, Martignetti, Angelo, Paris, Myriam, Tomcikova, Daniela, Boni, Luca, Falcone, Alfredo, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294477/
https://www.ncbi.nlm.nih.gov/pubmed/28081548
http://dx.doi.org/10.1038/bjc.2016.413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294477/
https://www.ncbi.nlm.nih.gov/pubmed/28081548
http://dx.doi.org/10.1038/bjc.2016.413

Ejemplares similares